Sam Hibbitts
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Sam Hibbitts has a total of 30 co-authors. Here are the top co-authors by number of shared publications:
A N Fiander
Department of Obstetrics & Gynaecology, School of Medicine, Cardiff University Heath Park, Cardiff CF14 4XN, UK
2 shared publicationsA Tristram
Department of Obstetrics & Gynaecology, School of Medicine, Cardiff University Heath Park, Cardiff CF14 4XN, UK
2 shared publications- Alison Fiander
School of Medicine, Cardiff University
2 shared publications - Amanda Tristram
School of Medicine, Heath Park, Cardiff University, CF64 3RL, UK
2 shared publications - Dean Bryant
University of Southampton, Southampton, United Kingdom
2 shared publications J McRea
Department of Cytology, Llandough Hospital, Cardiff and Vale NHS Trust CF64 2XX, UK
2 shared publications
Latest Publications
- 1 May 2015
- Published by Elsevier in Journal of Clinical Virology
- Vol. 66, 66-71
Human papillomavirus type 16 L1/L2 DNA methylation shows weak association with cervical disease grade in young women
- 1 May 2015
- Published by Elsevier in Journal of Clinical Virology
- Vol. 66, 66-71
Human papillomavirus type 16 L1/L2 DNA methylation shows weak association with cervical disease grade in young women
- 1 November 2014
- Published by Elsevier in Journal of Clinical Virology
- Vol. 61 (3) , 393-399
Increased methylation of Human Papillomavirus type 16 DNA correlates with viral integration in Vulval Intraepithelial Neoplasia
- 1 November 2014
- Published by Elsevier in Journal of Clinical Virology
- Vol. 61 (3) , 393-399
Increased methylation of Human Papillomavirus type 16 DNA correlates with viral integration in Vulval Intraepithelial Neoplasia
- 1 February 2014
- Published by Elsevier in Journal of Clinical Virology
- Vol. 59 (2) , 109-114
UK population based study to predict impact of HPV vaccination
- 1 February 2014
- Published by Elsevier in Journal of Clinical Virology
- Vol. 59 (2) , 109-114
UK population based study to predict impact of HPV vaccination
- 1 October 2010
- Vol. 12 (5) , 598-606
TA-CIN, a vaccine incorporating a recombinant HPV fusion protein (HPV16 L2E6E7) for the potential treatment of HPV16-associated genital diseases.
Commercially available prophylactic HPV vaccines for cervical cancer prevention have limited use in women with previous viral exposure. Therefore, a therapeutic HPV vaccine would benefit patients with HPV-associated genital diseases. Being developed by Cancer Research Technology Ltd, under license from Xenova Group plc, TA-CIN (Tissue Antigen - Cervical Intraepithelial Neoplasia) is a fusion protein vaccine comprising the HPV16 viral proteins L2, E6 and E7 for the treatment of HPV16-associated genital diseases. In mouse models, TA-CIN induced dose-dependent HPV16-specific CD4 and CD8 T-cell responses, which were enhanced when boosted with the vaccinia-based vector vaccine TA-HPV (Therapeutic Antigen - HPV). A phase I clinical trial of TA-CIN in healthy volunteers reported no serious adverse events and HPV16-specific cellular immune responses. Phase II trials in patients with anogenital and vulval intraepithelial neoplasia investigated heterologous prime/boost strategies with TA-CIN/TA-HPV and TA-HPV/TA-CIN, but neither of the regimens offered advantages over single-agent TA-HPV. A recent phase II trial investigating imiquimod/TA-CIN in patients with vulval intraepithelial neoplasia demonstrated significant infiltration of CD4 and CD8 T-cells in lesion responders and complete lesion regression in 63% of patients. More comprehensive case-controlled trials are needed to define responders to immunotherapy with TA-CIN and verify its prophylactic and therapeutic properties.
- 1 October 2010
- Vol. 12 (5) , 598-606
TA-CIN, a vaccine incorporating a recombinant HPV fusion protein (HPV16 L2E6E7) for the potential treatment of HPV16-associated genital diseases.
Commercially available prophylactic HPV vaccines for cervical cancer prevention have limited use in women with previous viral exposure. Therefore, a therapeutic HPV vaccine would benefit patients with HPV-associated genital diseases. Being developed by Cancer Research Technology Ltd, under license from Xenova Group plc, TA-CIN (Tissue Antigen - Cervical Intraepithelial Neoplasia) is a fusion protein vaccine comprising the HPV16 viral proteins L2, E6 and E7 for the treatment of HPV16-associated genital diseases. In mouse models, TA-CIN induced dose-dependent HPV16-specific CD4 and CD8 T-cell responses, which were enhanced when boosted with the vaccinia-based vector vaccine TA-HPV (Therapeutic Antigen - HPV). A phase I clinical trial of TA-CIN in healthy volunteers reported no serious adverse events and HPV16-specific cellular immune responses. Phase II trials in patients with anogenital and vulval intraepithelial neoplasia investigated heterologous prime/boost strategies with TA-CIN/TA-HPV and TA-HPV/TA-CIN, but neither of the regimens offered advantages over single-agent TA-HPV. A recent phase II trial investigating imiquimod/TA-CIN in patients with vulval intraepithelial neoplasia demonstrated significant infiltration of CD4 and CD8 T-cells in lesion responders and complete lesion regression in 63% of patients. More comprehensive case-controlled trials are needed to define responders to immunotherapy with TA-CIN and verify its prophylactic and therapeutic properties.
Should boys receive the human papillomavirus vaccine? Yes
Many countries have implemented HPV vaccination programmes for girls. Sam Hibbitts argues that they will not be fully effective unless extended to boys, but Kate Cuschieri (doi:10.1136/bmj.b4921) says the benefit is insufficient
Should boys receive the human papillomavirus vaccine? Yes
Many countries have implemented HPV vaccination programmes for girls. Sam Hibbitts argues that they will not be fully effective unless extended to boys, but Kate Cuschieri (doi:10.1136/bmj.b4921) says the benefit is insufficient
- Open Access
- 28 October 2008
- Published by Springer Nature in British Journal of Cancer
- Vol. 99 (11) , 1929-1933
Human papillomavirus prevalence in women attending routine cervical screening in South Wales, UK: a cross-sectional study
In this cross-sectional population-based study we determine human papillomavirus (HPV) prevalence in South Wales to provide comprehensive baseline data for future assessment of the impact of prophylactic HPV vaccination and to help inform future screening strategies. Liquid-based cytology samples from women attending routine cervical screening were collected (n=10 000: mean age 38 years, 93% cytology negative, and 64.8% from the 50% least deprived LSOA according to social deprivation score (SDS)). High-Risk (HR) and Low-Risk HPV screening was performed using HPV PCR-EIA with genotyping of HR positives and data correlated with age, SDS and cytology. Overall HPV prevalence was 13.5% (9.3% age standardised) and the most frequent HR types were HPV 16, 31, 18 and 58. In HR HPV-positive cases 42.4% had a single HR type and they were predominant in women with severe cytological abnormalities. Here, 66% of all HR HPV cases were in women aged 30 years of age or less and SDS had no significant effect on HPV status. HPV prevalence increased significantly with degree of dyskarosis from 7% in cytology negative samples to 80% in samples with severe cytological abnormalities (P-value <0.0001). Overall, 46% of HR HPV cases were positive for the two HR types targeted by the prophylactic vaccines (HPV 16 and HPV 18). The data presented represents the largest type-specific investigation of HPV prevalence in an unselected UK population.
- 28 October 2008
- Published by Springer Nature in British Journal of Cancer
- Vol. 99 (11) , 1929-1933
Open AccessHuman papillomavirus prevalence in women attending routine cervical screening in South Wales, UK: a cross-sectional study
In this cross-sectional population-based study we determine human papillomavirus (HPV) prevalence in South Wales to provide comprehensive baseline data for future assessment of the impact of prophylactic HPV vaccination and to help inform future screening strategies. Liquid-based cytology samples from women attending routine cervical screening were collected (n=10 000: mean age 38 years, 93% cytology negative, and 64.8% from the 50% least deprived LSOA according to social deprivation score (SDS)). High-Risk (HR) and Low-Risk HPV screening was performed using HPV PCR-EIA with genotyping of HR positives and data correlated with age, SDS and cytology. Overall HPV prevalence was 13.5% (9.3% age standardised) and the most frequent HR types were HPV 16, 31, 18 and 58. In HR HPV-positive cases 42.4% had a single HR type and they were predominant in women with severe cytological abnormalities. Here, 66% of all HR HPV cases were in women aged 30 years of age or less and SDS had no significant effect on HPV status. HPV prevalence increased significantly with degree of dyskarosis from 7% in cytology negative samples to 80% in samples with severe cytological abnormalities (P-value <0.0001). Overall, 46% of HR HPV cases were positive for the two HR types targeted by the prophylactic vaccines (HPV 16 and HPV 18). The data presented represents the largest type-specific investigation of HPV prevalence in an unselected UK population.
- Open Access
- 4 July 2006
- Published by Springer Nature in British Journal of Cancer
- Vol. 95 (2) , 226-232
Human papillomavirus infection: an Anonymous Prevalence Study in South Wales, UK
- 4 July 2006
- Published by Springer Nature in British Journal of Cancer
- Vol. 95 (2) , 226-232
Open AccessHuman papillomavirus infection: an Anonymous Prevalence Study in South Wales, UK